GALAPAGOS NV-SPON ADR (GLPG) Fundamental Analysis & Valuation
NASDAQ:GLPG • US36315X1019
33.69 USD
+0.64 (+1.94%)
At close: Mar 4, 2026
33.69 USD
0 (0%)
After Hours: 3/4/2026, 8:00:01 PM
This GLPG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
GLPG gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. GLPG has an average financial health and profitability rating. While showing a medium growth rate, GLPG is valued expensive at the moment.
1. GLPG Profitability Analysis
1.1 Basic Checks
- In the past year GLPG was profitable.
- GLPG had a negative operating cash flow in the past year.
- In multiple years GLPG reported negative net income over the last 5 years.
- GLPG had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- GLPG has a Return On Assets of 9.42%. This is amongst the best in the industry. GLPG outperforms 93.46% of its industry peers.
- GLPG has a better Return On Equity (9.92%) than 93.27% of its industry peers.
- GLPG has a Return On Invested Capital of 12.70%. This is amongst the best in the industry. GLPG outperforms 95.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.42% | ||
| ROE | 9.92% | ||
| ROIC | 12.7% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 28.85%, GLPG belongs to the best of the industry, outperforming 95.19% of the companies in the same industry.
- With an excellent Operating Margin value of 47.04%, GLPG belongs to the best of the industry, outperforming 99.42% of the companies in the same industry.
- Looking at the Gross Margin, with a value of 97.33%, GLPG belongs to the top of the industry, outperforming 96.54% of the companies in the same industry.
- GLPG's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 47.04% | ||
| PM (TTM) | 28.85% | ||
| GM | 97.33% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.64%
GM growth 5YN/A
2. GLPG Health Analysis
2.1 Basic Checks
- GLPG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- There is no outstanding debt for GLPG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 8.65 indicates that GLPG is not in any danger for bankruptcy at the moment.
- With an excellent Altman-Z score value of 8.65, GLPG belongs to the best of the industry, outperforming 80.19% of the companies in the same industry.
- GLPG has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
- The Debt to Equity ratio of GLPG (0.00) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.65 |
ROIC/WACC1.59
WACC8%
2.3 Liquidity
- A Current Ratio of 20.15 indicates that GLPG has no problem at all paying its short term obligations.
- GLPG has a better Current ratio (20.15) than 95.77% of its industry peers.
- GLPG has a Quick Ratio of 20.00. This indicates that GLPG is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 20.00, GLPG belongs to the top of the industry, outperforming 95.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 20.15 | ||
| Quick Ratio | 20 |
3. GLPG Growth Analysis
3.1 Past
- GLPG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 334.82%, which is quite impressive.
- The Revenue has grown by 280.53% in the past year. This is a very strong growth!
- GLPG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.97% yearly.
EPS 1Y (TTM)334.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3023.68%
Revenue 1Y (TTM)280.53%
Revenue growth 3Y58.87%
Revenue growth 5Y15.97%
Sales Q2Q%1093.16%
3.2 Future
- Based on estimates for the next years, GLPG will show a very negative growth in Earnings Per Share. The EPS will decrease by -23.16% on average per year.
- Based on estimates for the next years, GLPG will show a very negative growth in Revenue. The Revenue will decrease by -30.71% on average per year.
EPS Next Y-150.44%
EPS Next 2Y-64.81%
EPS Next 3Y-30.23%
EPS Next 5Y-23.16%
Revenue Next Year-0.05%
Revenue Next 2Y-2.62%
Revenue Next 3Y-0.5%
Revenue Next 5Y-30.71%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. GLPG Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 5.94, the valuation of GLPG can be described as very cheap.
- Based on the Price/Earnings ratio, GLPG is valued cheaply inside the industry as 98.46% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 27.03. GLPG is valued rather cheaply when compared to this.
- The Forward Price/Earnings Ratio is negative for GLPG. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.94 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- GLPG's earnings are expected to decrease with -30.23% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-64.81%
EPS Next 3Y-30.23%
5. GLPG Dividend Analysis
5.1 Amount
- GLPG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
GLPG Fundamentals: All Metrics, Ratios and Statistics
33.69
+0.64 (+1.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24 2026-02-24/bmo
Earnings (Next)N/A N/A
Inst Owners24.93%
Inst Owner Change-0.24%
Ins Owners0%
Ins Owner ChangeN/A
Market Cap2.22B
Revenue(TTM)1.11B
Net Income(TTM)320.88M
Analysts52.22
Price Target37.13 (10.21%)
Short Float %1.53%
Short Ratio6.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9817.73%
Min EPS beat(2)-19965.4%
Max EPS beat(2)329.9%
EPS beat(4)1
Avg EPS beat(4)-5598.11%
Min EPS beat(4)-19965.4%
Max EPS beat(4)329.9%
EPS beat(8)4
Avg EPS beat(8)-2634.25%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)487.53%
Min Revenue beat(2)-2.86%
Max Revenue beat(2)977.92%
Revenue beat(4)2
Avg Revenue beat(4)242.29%
Min Revenue beat(4)-10.27%
Max Revenue beat(4)977.92%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.38%
PT rev (3m)8.91%
EPS NQ rev (1m)-0.12%
EPS NQ rev (3m)0.19%
EPS NY rev (1m)-0.12%
EPS NY rev (3m)13.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.94 | ||
| Fwd PE | N/A | ||
| P/S | 1.71 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.59 | ||
| P/tB | 0.59 | ||
| EV/EBITDA | N/A |
EPS(TTM)5.67
EY16.83%
EPS(NY)-2.86
Fwd EYN/A
FCF(TTM)-4.8
FCFYN/A
OCF(TTM)-4.55
OCFYN/A
SpS19.66
BVpS57.2
TBVpS57.19
PEG (NY)N/A
PEG (5Y)N/A
Graham Number85.43
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.42% | ||
| ROE | 9.92% | ||
| ROCE | 16.08% | ||
| ROIC | 12.7% | ||
| ROICexc | 161.69% | ||
| ROICexgc | 162.23% | ||
| OM | 47.04% | ||
| PM (TTM) | 28.85% | ||
| GM | 97.33% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.64%
GM growth 5YN/A
F-Score6
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 1.25% | ||
| Interest Coverage | 1127.48 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 20.15 | ||
| Quick Ratio | 20 | ||
| Altman-Z | 8.65 |
F-Score6
WACC8%
ROIC/WACC1.59
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)13.02%
Cap/Sales(5y)12.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)334.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3023.68%
EPS Next Y-150.44%
EPS Next 2Y-64.81%
EPS Next 3Y-30.23%
EPS Next 5Y-23.16%
Revenue 1Y (TTM)280.53%
Revenue growth 3Y58.87%
Revenue growth 5Y15.97%
Sales Q2Q%1093.16%
Revenue Next Year-0.05%
Revenue Next 2Y-2.62%
Revenue Next 3Y-0.5%
Revenue Next 5Y-30.71%
EBIT growth 1Y377.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.73%
EBIT Next 3Y21.58%
EBIT Next 5Y15%
FCF growth 1Y32.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.55%
OCF growth 3YN/A
OCF growth 5YN/A
GALAPAGOS NV-SPON ADR / GLPG FAQ
What is the fundamental rating for GLPG stock?
ChartMill assigns a fundamental rating of 4 / 10 to GLPG.
Can you provide the valuation status for GALAPAGOS NV-SPON ADR?
ChartMill assigns a valuation rating of 2 / 10 to GALAPAGOS NV-SPON ADR (GLPG). This can be considered as Overvalued.
What is the profitability of GLPG stock?
GALAPAGOS NV-SPON ADR (GLPG) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for GLPG stock?
The Price/Earnings (PE) ratio for GALAPAGOS NV-SPON ADR (GLPG) is 5.94 and the Price/Book (PB) ratio is 0.59.